Back to top anchor

Understanding the role of IgG3 in acute rheumatic fever

Year:
2020
Duration:
36 months
Approved budget:
$1,187,148.95
Researchers:
Associate Professor Nicole Moreland
,
Dr Amy Chung
,
Associate Professor Nigel Wilson
,
Dr David Crossman
,
Professor Michael Baker
Health issue:
Infectious disease
Proposal type:
Project
Lay summary
Rheumatic fever (RF) is one of New Zealand’s starkest examples of health inequity, with Māori and Pacific children 20-40 times more likely than all other New Zealand children to develop the disease. RF is triggered by Streptococcus A (StrepA) infections and can develop into chronic rheumatic heart disease (RHD). There is currently a complete lack of treatment options available to RF patients to halt cardiac damage and progression to RHD. Improved understanding of RF disease mechanisms is urgently needed to determine pathways that could be targeted by existing drugs to reduce progression. We observed a marked elevation of a particular antibody type (subclass IgG3) in RF patients and will use advanced laboratory methods to map the immune mechanisms associated with this increase. This will identify intervention pathways that may be interrupted by immune modulating drugs already in clinical use for other diseases with the potential to stop RF patients developing chronic RHD.